



23rd July, 2014

dorsaVi welcomes first US sale of ViPerform

Melbourne, Australia: Australian wearable medical device company dorsaVi Limited (ASX: DVL) has today announced the sale of its first motion analysis device technology, ViPerform, in the United States.

ViPerform, dorsaVi's product for elite athletes and teams, is now available at Metro Orthopaedics and Sports Therapy (MOST) in Silver Spring, Maryland just outside Washington DC.

ViPerform consists of small wearable sensors that are placed on the body and provide immediate analysis and biofeedback on movement and muscle activity to a PC, tablet or small recording device.

MOST is an internationally recognised sports medicine, spine and performance practice which provides comprehensive sports training and injury recovery programs for elite athletes and members of the general public.

Dr. Mehul J. Desai is a Physical Medicine and Rehabilitation (PM&R) specialist who consults at MOST and has completed fellowship training in Pain Medicine. He also earned his Masters in Public Health and is an accomplished and published researcher on many topics. Dr Desai will be working with the athletic trainers and physical therapists at MOST, using ViPerform to help maximise athletes' potential and also using the objective data from ViPerform for research projects.

"Increasingly in our healthcare environment we seek means by which to measure function objectively, and to some extent our inability to do so in the past has limited the opportunity to customize treatment measures for patients," said Dr Desai.

"ViPerform provides objective information to the clinician who will then gain the opportunity to integrate this data and personalise care for their patient. One of the most exciting features is the ability to capture this information anywhere, whether that be at home, work or on the sports field."

dorsaVi CEO Andrew Ronchi said the Company had worked hard to establish a strong US sales team in the clinical and sports area and is excited to already see these appointments paying off with the first sale of ViPerform to such a prestigious healthcare practice.

"These strategic appointments are already paying off following the sale of ViPerform to Metro Orthopaedics and Sports Therapy, a well known and highly regarded interdisciplinary healthcare practice that employs orthopaedic surgeons, physical medicine specialists, sports medicine specialists, and pain medicine specialists as well as physical therapists and athletic trainers," said Mr Ronchi.

dorsaVi US President John Kowalczyk said, "This is a huge milestone for dorsaVi USA. We know this will be the first of many clinics to adopt ViPerform here."

"Dr Desai and Metro Orthopaedics and Sports Therapy will forever be part of our business history as the first to lease ViPerform in the US. I could not be more excited about the possibilities of what we can do here," said Mr Kowalczyk.

The first sale of ViPerform comes as dorsaVi's clinical product, ViMove, received FDA clearance in the United States, one of the biggest market opportunities for dorsaVi with approximately 280,000 physiotherapists and 660,000 physicians.

-ENDS-

For more information or to arrange an interview, please contact:

MEDIA

Tahlia Weston
Buchan Consulting
0450 606 950

tweston@buchanwe.com.au

INVESTOR

Rebecca Wilson
Buchan Consulting
0417 382 391

rwilson@buchanwe.com.au

About dorsaVi

dorsaVi (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** ViMove is transforming the management of patients by providing objective assessment, monitoring outside the clinic and immediate biofeedback. ViMove is currently used by medical and physiotherapy practices in Australia and the United Kingdom and is now available in the United States following FDA 510K clearance.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used by AFL and NRL clubs in Australia, clubs in the Barclays Premier League, Australian and Victorian Institutes of Sport, various Olympic teams and athletes internationally, and Cricket Australia.
- **OH&S:** We combine innovation, measurement and quality to reduce workplace incidents, costs, meet compliance and improve brand reputation. ViSafe enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. ViSafe has been used by major corporations including Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton. Australian Workplace Compliance (AWC) delivers risk mitigation through compliance to OHS, Quality Management Systems, Company Policy and Process.

Further information is available at www.dorsavi.com.